Mountaineer Biomarker Study: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HET2+ Metastatic Colorectal Cancer.

Administered By

Medicine, Medical Oncology

Awarded By

Seattle Genetics, Inc

Contributors

Nixon, Andrew Benjamin Principal Investigator

Start/End

April 7, 2020 - April 30, 2023